Erythropoietin receptor (EpoR) is a receptor present on erythroid progenitor cells, belonging to the type I cytokine receptor family and characterized by a single transmembrane domain. When EpoR binds to erythropoietin (EPO), it effectively inhibits cell apoptosis and stimulates the production of red blood cells.
Activation of EpoR leads to the activation of downstream intracellular signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) pathway, and the signal transducer and activator of transcription (STAT) pathway.
In erythroid lineage cells, the expression of EpoR is crucial for the normal development of mammals. Furthermore, EpoR plays a pivotal role in the complex cascade responses to acute and chronic hypoxic injuries in the body, particularly within the cardiovascular system. EpoR has driven research into the beneficial effects of erythropoietin in various diseases, primarily cardiovascular diseases[1].
ASP7967 hemifumarate 是一种口服有效的 RNA 适体 AC17-4 配体(Kd 为 12 nM),通过结合 AC17-4 调节适体酶型和外显子跳跃型核糖开关,从而在不依赖外源蛋白因子的情况下实现小分子控制的转基因表达,可用于合成 RNA 开关、基因表达调控及 AAV 基因疗法相关表达控制研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号